Collaboration brings together global expertise in psychometric measurement and patient-centric digital solutions to accelerate next-generation clinical trials.

Shanghai, China – 25AUG2025 – Valis Bioscience, a leader in optimizing psychometric measurement for central nervous system (CNS) clinical trials, today announced a strategic partnership with Xincere Med, a pioneering provider of patient-centric eCOA (electronic Clinical Outcome Assessment) and decentralized clinical trial (DCT) solutions across China, the Asia-Pacific region, and globally.

This collaboration combines Valis Bioscience’s expertise in enhancing reliability and validity in CNS clinical research—through best-in-class rater training, clinical data validation, and secure video/data acquisition technologies—with Xincere Med’s intelligent digital platforms designed to support remote and hybrid trial models. Together, the companies aim to set new standards for data quality, patient engagement, and operational efficiency in clinical development.

Xincere Med’s AI-enabled platform enables sponsors and CROs to conduct clinical trials remotely, improving accessibility, reducing patient burden, and supporting diverse recruitment. When paired with Valis Bioscience’s rigorous training and validation methodologies, the partnership offers sponsors an integrated solution that elevates both the scientific and operational dimensions of clinical trials.